Published in:
01-06-2011 | Gastrointestinal Oncology
Hyperthermic Intraperitoneal Chemotherapy in Advanced Gastric Cancer: The End of Skepticism?
Authors:
Olivier Glehen, MD, PhD, François Noël Gilly, MD, PhD, Eddy Cotte, MD
Published in:
Annals of Surgical Oncology
|
Issue 6/2011
Login to get access
Excerpt
Over the past two decades, novel therapeutic approaches to peritoneal carcinomatosis (PC) have emerged, combining cytoreductive surgery and peritonectomy procedures with perioperative intraperitoneal chemotherapy (PIC), including hyperthermic intraperitoneal chemotherapy (HIPEC) and/or early postoperative intraperitoneal chemotherapy (EPIC). Theoretically, cytoreductive surgery is performed to treat macroscopic disease and PIC to treat microscopic residual disease aiming to remove disease completely with a single procedure. Many consider it a standard of care for disease such as pseudomyxoma peritonei, peritoneal mesothelioma, or localized and resectable colorectal carcinomatosis.
1 Because of its negative prognosis, the question regarding the efficiency of this combined procedure still remains controversial for carcinomatosis from gastric origin. …